BioWorld

April 10, 2007

View Archived Issues

Sirion Series B Raises $45M For Phase III Ophthalmic Bid

Ophthalmics-targeted Sirion Therapeutics Inc. pulled down $45 million in a Series B financing to boost a pipeline led by ST-601, the Phase III emulsion acquired last year for inflamed eyes. (BioWorld Today) Read More

Senate Schedules Stem Cell Debate And Vote For Today

Read More

Alteon Raising $25M Privately, Expanding Rights To ALT-2074

Read More

Melior Grants Pfizer Access To Multiplexed In Vivo Platform

Read More

EPA Awards $111M In BioPharma Contracts

Read More

Appointments And Advancements

Read More

Other News To Note

Read More

Clinic Roundup

Read More

Financings Roundup

Read More